Qelbree Administration Timing for Optimal ADHD Symptom Management

Rationale for Morning Administration

• The American College of Pharmacology recommends viloxazine extended-release (Qelbree) to be administered once daily in the morning for optimal management of ADHD symptoms with minimal adverse effects, providing "around-the-clock" symptom control throughout the day 1, 2
• Viloxazine extended-release (Qelbree) is designed for once-daily dosing, with a recommended starting dose of 200 mg taken orally once daily, and morning administration is preferred for non-stimulant ADHD medications like viloxazine 3

Dosing Considerations

• The recommended titration schedule for viloxazine is to increase by 200 mg increments at weekly intervals based on response and tolerability, with a maximum daily dose of 600 mg/day 3

Special Populations

• Limited data are available on the efficacy, safety, and tolerability of viloxazine for the treatment of ADHD in adults, and there is no published information on viloxazine's safety during pregnancy or breastfeeding, making alternative agents preferable in these populations 3, 4

Common Pitfalls and Caveats

• Unlike some other non-stimulant medications, viloxazine does not have specific recommendations for evening dosing, and treatment effects of non-stimulants like viloxazine are not usually observed until several weeks after initiation (2-4 weeks) 1, 2